SMAD4 and metastatic colorectal cancer: Given the lack of a validation cohort in Pan’s study and the limited sample size of patients with concurrent SMAD4 and TP53-GOF mutation in our cohort, the impact of TP53-GOF mutation on the prognosis of metastatic colorectal cancer remains to be determined.